

Wenjun Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11904483/publications.pdf>

Version: 2024-02-01

8
papers

301
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

565
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury. <i>Redox Biology</i> , 2014, 2, 314-322.	9.0	96
2	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. <i>Blood Advances</i> , 2018, 2, 2039-2051.	5.2	54
3	Dietary Antioxidants Significantly Attenuate Hyperoxia-Induced Acute Inflammatory Lung Injury by Enhancing Macrophage Function via Reducing the Accumulation of Airway HMGB1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 977.	4.1	52
4	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I κ B. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2564-2574.	4.1	37
5	The Compromise of Macrophage Functions by Hyperoxia Is Attenuated by Ethacrynic Acid via Inhibition of NF- κ B-Mediated Release of High-Mobility Group Box-1. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 52, 171-182.	2.9	23
6	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. <i>Blood Cancer Journal</i> , 2021, 11, 39.	6.2	22
7	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. <i>Blood Advances</i> , 2021, 5, 185-197.	5.2	11
8	Potential Synergy Mechanism of Processing Methods for the Basic Remedies of Qixue Shuangbu Prescription Based on Integrated Metabolomics Strategy and Network Pharmacology Study. <i>Journal of Chromatographic Science</i> , 2021, 59, 983-993.	1.4	6